Difference between revisions of "Okroj M, et al. Cancer Treat. Rev. (2013) cited as Ref 717 in DOI: 10.1038/s41392-020-0110-5 (Q9980)"

From Wikibase.slis.ua.edu
Jump to navigation Jump to search
(‎Created claim: DOI Identifier (P138): 10.1016/j.ctrv.2012.10.008, #quickstatements; #temporary_batch_1590000649558)
(‎Created claim: Page(s) (P105): 632-639, #quickstatements; #temporary_batch_1590074839150)
 
(5 intermediate revisions by the same user not shown)
Property / PubMed ID
 +
Property / PubMed ID: 23219151 / rank
 +
Normal rank
Property / Publication Date
 +
2013
Timestamp+2013-01-01T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 year
Before0
After0
Property / Publication Date: 2013 / rank
 +
Normal rank
Property / Published In Name String
 +
Cancer Treat. Rev.
Property / Published In Name String: Cancer Treat. Rev. / rank
 +
Normal rank
Property / Volume
 +
39
Property / Volume: 39 / rank
 +
Normal rank
Property / title
 +
Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignancies (English)
Property / title: Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignancies (English) / rank
 +
Normal rank
Property / Page(s)
 +
632-639
Property / Page(s): 632-639 / rank
 +
Normal rank

Latest revision as of 15:50, 21 May 2020

Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
Language Label Description Also known as
English
Okroj M, et al. Cancer Treat. Rev. (2013) cited as Ref 717 in DOI: 10.1038/s41392-020-0110-5
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8

    Statements

    Okroj M
    0 references
    Osterborg A
    0 references
    Blom AM
    0 references
    0 references
    2013
    0 references
    Cancer Treat. Rev.
    0 references
    39
    0 references
    Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignancies (English)
    0 references
    632-639
    0 references